180 Life Sciences Buchwert je Aktie
Was ist das Buchwert je Aktie von 180 Life Sciences?
Buchwert je Aktie von 180 Life Sciences Corp. ist -0.02
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit buchwert je aktie ähnlich 180 Life Sciences
- Proteo hat Buchwert je Aktie von -0.02
- HFX hat Buchwert je Aktie von -0.02
- Aequus Pharmaceuticals hat Buchwert je Aktie von -0.02
- Shekel Brainweigh hat Buchwert je Aktie von -0.02
- Pascal Biosciences hat Buchwert je Aktie von -0.02
- Globally Local Technologies hat Buchwert je Aktie von -0.02
- 180 Life Sciences hat Buchwert je Aktie von -0.02
- Duesenberg Technologies hat Buchwert je Aktie von -0.02
- Memex hat Buchwert je Aktie von -0.02
- Branded Legacy Inc hat Buchwert je Aktie von -0.02
- Synstream hat Buchwert je Aktie von -0.02
- BioPharmX hat Buchwert je Aktie von -0.02
- Achiko AG hat Buchwert je Aktie von -0.02